On May 22nd, Jin10 Data reported that the Pudong New Area Biomedical Industry Innovation and Development Conference was held at the Pudong New Area Office Center. It was learned at the conference that this year, Pudong New Area in Shanghai has approved the marketing of 3 innovative drugs, and there are 16 new drugs in the application phase for marketing. Up to now, there have been 24 domestic innovative drugs approved for marketing in Pudong New Area. The conference also released the 2024 achievements of biomedical innovation in Pudong New Area, including Kaixing Life's CAR-T cell therapy Zekoviola Injection (Sai Kaize®), Kechow Pharmaceutical's first domestically produced MEK inhibitor Trametinib Capsules (Ke Luping®), Beida Pharmaceutical's third-generation EGFR inhibitor Rizotinib Hydrochloride Capsules (Rui Bida®), etc.